In this episode from the series “Key Decisions in HIV Care,” Jonathan Appelbaum, MD, FACP, AAHIVS, and Jens D. Lundgren, MD, DMSc, discuss important considerations for antiretroviral therapy (ART) use in older patients with renal and hepatic impairment.European AIDS Clinical Society guideline screening recommendations for kidney disease in people with HIVAntiretroviral dose adjustment recommendations based on estimated glomerular filtration rateData on the use of full-dose lamivudine with renal impairmentData on the use of 2-drug nucleos(t)ide reverse-transcriptase inhibitor–sparing ART regimens, including GEMINI-1 and -2, TANGO, and SALSA for dolutegravir/lamivudine; SWORD-1 and -2 for dolutegravir/lamivudine; and ATLAS and FLAIR for long-acting cabotegravir plus rilpivirineUS Department of Health and Human Services recommendations on the use of ART agents with hepatic impairmentRecommendations from the American Gastroenterological Association on screening and diagnosis of nonalcoholic fatty liver disease (NAFLD)Prevalence of NAFLD, nonalcoholic steatohepatitis, and liver fibrosis in people with HIVOverlapping risk factors between HIV and NAFLDPresenters:Jonathan Appelbaum, MD, FACP, AAHIVSLaurie L. Dozier Jr, MD, Education DirectorProfessor of Internal MedicineChair, Department of Clinical SciencesFlorida State University College of MedicineTallahassee, Florida Jens D. Lundgren, MD, DMScProfessorRigshospital, University of CopenhagenDirectorCentre of Excellence for Health, Immunity and Infection (CHIP)Rigshospital, University of CopenhagenCopenhagen, Denmark Content based on an online CME program supported by educational grants from Gilead Sciences, Inc.; Janssen Therapeutics, Division of Janssen Products, LP; and ViiV Healthcare.Follow along with the slides at:https://bit.ly/3gAsu19Link to full program:https://bit.ly/3fOl0XX